Market Intelligence, Clinical Progress, and High-Purity Reagents for PTEN-Deficient Oncology and Rare Disease Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTEN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTEN Recombinant Protein (Wild-Type & Key Mutants) High purity (>95%), Endotoxin Controlled. Sequence Verified. Available in E. coli or mammalian expression systems to preserve native phosphorylation states. |
View PTEN Products |
| Gene Delivery | PTEN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for reconstituting PTEN expression in PTEN-null background cell lines (e.g., PC-3, U-87 MG) to validate downstream signaling. |
View PTEN Products |
| Benchmark Ab | Anti-PTEN Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and Flow Cytometry. |
View PTEN Products |
| Validator | PTEN siRNA Set For target knockdown verification in wild-type cell lines to mimic PTEN loss-of-function phenotypes. |
View PTEN Products |
| Related Target A | USP7 Deubiquitinase that regulates PTEN nuclear export and stability. Inhibiting USP7 promotes PTEN-mediated tumor suppression. |
View USP7 Products |
| Related Target B | PIK3CA The primary downstream driver activated upon PTEN loss. Crucial for synthetic lethality screening and combination therapy assays. |
View PIK3CA Products |
| Related Target C | AKT1 Downstream kinase in the PI3K/Akt/mTOR pathway. Essential readout for PTEN functional restoration assays. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing lipid vs. protein phosphatase activity | Specific mutant proteins (e.g., G129R lipid-dead, C124S total-dead) available with verified sequences and high purity (>95%) |
| In vitro screening for PTEN stabilizers | Homogeneous recombinant PTEN proteins with controlled endotoxin levels and batch-to-batch consistency |
| Lack of Controls for PTEN-loss models | Sequence-verified clinical benchmark antibodies and validated siRNA sets included for specificity checks |
| False positives in phenotypic assays | Lentivirus-mediated stable rescue lines available to confirm target-specific rescue of PTEN-null phenotypes |
Live PTEN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTEN therapeutics is intensifying, with major players shifting focus from traditional indirect pathway inhibition to direct PTEN restoration and synthetic lethality strategies. As first-generation PI3K/AKT inhibitors reach the clinic, the next wave of R&D is targeting the reactivation of endogenous PTEN through USP7/NEDD4-1 inhibition, mRNA-based PTEN delivery, and targeting PTEN-deficient tumors via selective PI3K-beta or PARP inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (USP7 Inhibitors) | Novartis, Roche | Prostate Cancer, Glioblastoma | PTEN stability assay (Need high-purity recombinant PTEN & USP7 proteins) |
| mRNA Therapeutics (PTEN Restoration) | Translate Bio / Sanofi | Astrocytoma, Triple-Negative Breast Cancer | Intracellular expression validation (Need PTEN stable cell lines & benchmark Abs) |
| Small Molecule (PI3K-beta Selective) | AstraZeneca, Incyte | PTEN-deficient Solid Tumors | Selectivity assays (Need mutant vs. WT PTEN cell models & downstream pathway readouts) |